[{"address1": "3891 Ranchero Drive", "address2": "Suite 150", "city": "Ann Arbor", "state": "MI", "zip": "48108", "country": "United States", "phone": "734 887 3903", "website": "https://www.esperion.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.", "fullTimeEmployees": 304, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sheldon L. Koenig M.B.A.", "age": 58, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1262378, "exercisedValue": 0, "unexercisedValue": 18056}, {"maxAge": 1, "name": "Mr. Benjamin  Halladay M.B.A.", "age": 38, "title": "Chief Financial Officer", "yearBorn": 1986, "fiscalYear": 2024, "totalPay": 713958, "exercisedValue": 0, "unexercisedValue": 5625}, {"maxAge": 1, "name": "Mr. Benjamin O. Looker J.D.", "age": 42, "title": "General Counsel & Corporate Secretary", "yearBorn": 1982, "fiscalYear": 2024, "totalPay": 696350, "exercisedValue": 0, "unexercisedValue": 4219}, {"maxAge": 1, "name": "Mr. Glenn P. Brame", "age": 67, "title": "Chief Technical Operations Officer", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Tiffany  Aldrich M.B.A.", "title": "Associate Director of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Betty Jean Swartz", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "LeAnne  Bloedon M.S.", "title": "VP & Head of Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Harlow", "age": 49, "title": "Chief Commercial Officer", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen  Pinkosky", "title": "Vice President of Drug Discovery of Early Pre-Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.79, "open": 3.81, "dayLow": 3.675, "dayHigh": 3.83, "regularMarketPreviousClose": 3.79, "regularMarketOpen": 3.81, "regularMarketDayLow": 3.675, "regularMarketDayHigh": 3.83, "payoutRatio": 0.0, "beta": 1.009, "forwardPE": 18.65, "volume": 3176985, "regularMarketVolume": 3176985, "averageVolume": 7175546, "averageVolume10days": 7890700, "averageDailyVolume10Day": 7890700, "bid": 2.76, "ask": 3.91, "bidSize": 2, "askSize": 8, "marketCap": 884268224, "fiftyTwoWeekLow": 0.69, "fiftyTwoWeekHigh": 4.03, "allTimeHigh": 120.96, "allTimeLow": 0.69, "priceToSalesTrailing12Months": 2.910673, "fiftyDayAverage": 2.9612, "twoHundredDayAverage": 1.8463, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1392806272, "profitMargins": -0.34835997, "floatShares": 235435832, "sharesOutstanding": 237069239, "sharesShort": 24958080, "sharesShortPriorMonth": 24416434, "sharesShortPreviousMonthDate": 1760486400, "dateShortInterest": 1763078400, "sharesPercentSharesOut": 0.105299994, "heldPercentInsiders": 0.0044, "heldPercentInstitutions": 0.47278, "shortRatio": 4.16, "shortPercentOfFloat": 0.10569999, "impliedSharesOutstanding": 237069239, "bookValue": -2.197, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -105831000, "trailingEps": -0.54, "forwardEps": 0.2, "enterpriseToRevenue": 4.585, "enterpriseToEbitda": -47.578, "52WeekChange": -0.010443866, "SandP52WeekChange": 0.13287461, "quoteType": "EQUITY", "currentPrice": 3.73, "targetHighPrice": 16.0, "targetLowPrice": 1.72, "targetMeanPrice": 6.5025, "targetMedianPrice": 4.65, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 92447000, "totalCashPerShare": 0.39, "ebitda": -29274000, "totalDebt": 600985024, "quickRatio": 0.589, "currentRatio": 1.004, "totalRevenue": 303801984, "revenuePerShare": 1.538, "returnOnAssets": -0.05416, "grossProfits": 131898000, "freeCashflow": -78274248, "operatingCashflow": -93288000, "revenueGrowth": 0.691, "grossMargins": 0.43416, "ebitdaMargins": -0.09636, "operatingMargins": -0.11407, "financialCurrency": "USD", "symbol": "ESPR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "messageBoardId": "finmb_28236", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "epsTrailingTwelveMonths": -0.54, "epsForward": 0.2, "epsCurrentYear": -0.06714, "priceEpsCurrentYear": -55.555557, "fiftyDayAverageChange": 0.7688, "fiftyDayAverageChangePercent": 0.25962448, "twoHundredDayAverageChange": 1.8837, "twoHundredDayAverageChangePercent": 1.0202568, "priceToBook": -1.6977696, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "cryptoTradeable": false, "marketState": "CLOSED", "shortName": "Esperion Therapeutics, Inc.", "regularMarketChangePercent": -1.58311, "regularMarketPrice": 3.73, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1372253400000, "postMarketChangePercent": -0.00536282, "postMarketPrice": 3.7298, "postMarketChange": -0.00020003319, "regularMarketChange": -0.0599999, "regularMarketDayRange": "3.675 - 3.83", "corporateActions": [], "postMarketTime": 1764977200, "regularMarketTime": 1764968401, "exchange": "NGM", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 7175546, "fiftyTwoWeekLowChange": 3.04, "fiftyTwoWeekLowChangePercent": 4.405797, "fiftyTwoWeekRange": "0.69 - 4.03", "fiftyTwoWeekHighChange": -0.3000002, "fiftyTwoWeekHighChangePercent": -0.07444173, "fiftyTwoWeekChangePercent": -1.0443866, "earningsTimestamp": 1762435800, "earningsTimestampStart": 1762435800, "earningsTimestampEnd": 1762435800, "earningsCallTimestampStart": 1762434000, "earningsCallTimestampEnd": 1762434000, "isEarningsDateEstimate": false, "longName": "Esperion Therapeutics, Inc.", "displayName": "Esperion Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-12-06"}]